natgillin/translations-raw huggingface dataset:
Kravene til indsendelse af periodiske sikkerhedsopdateringer for dette lægemiddel er indstillet på listen over EU-referencedatoer (EURD liste), der er fastsat i henhold til artikel 107c (7), i direktiv 2001/83 / EF, og enhver efterfølgende opdatering offentliggjort på Det Europæiske Lægemiddelagenturs webportal.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Kravene til indsendelse af periodiske, opdaterede sikkerhedsindberetninger for dette lægemiddel, er fastsat i listen over EU-referencedatoer (EURD liste), der er fastsat i henhold til artikel 107c(7), i direktiv 2001/83/EF, og enhver efterfølgende opdatering offentliggjort på den europæiske webportal om lægemidler.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web- portal.
Kravene til indsendelse af PSUR’er for dette lægemiddel er fastsat i listen over EU-referencedatoer (EURD list), som fastsat i artikel 107c(7), i direktiv 2001/83/EF og enhver efterfølgende opdatering offentliggjort på den europæiske webportal for lægemidler.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Kravene til omgivelserne ved administration af Zalmoxis
The room requirements for Zalmoxis administration
Kravenefor fremsendelse af periodiske, opdaterede sikkerhedsindberetninger for dette lægemiddel fremgår af listen over EU-referencedatoer (EURD list), som fastsat i artikel 107c, stk.
The requirements for submission of periodic safety reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of
kravet om vaccinationer/profylaktisk antibiotisk behandling før behandling
the requirement for pre-treatment vaccinations/antibiotic prophylaxis the enrolment in the registries
KRd = Kyprolis, lenalidomid og dexamethason; Rd = lenalidomid og dexamethason; OS = samlet overlevelse; NE = kan ikke estimeres; HR = hazard ratio; CI = konfidensinterval
KRd = Kyprolis, lenalidomide and dexamethasone; Rd = lenalidomide and dexamethasone; OS = overall survival; NE = not estimable; HR = hazard ratio; CI = confidence interval
KRd = Kyprolis, lenalidomid og dexamethason; Rd = lenalidomid og dexamethason; PFS = progressionsfri overlevelse; HR = hazard ratio; CI = konfidensinterval; IMWG = International Myeloma Working Group; EBMT = European Group for Blood and Marrow Transplantation
KRd = Kyprolis, lenalidomide and dexamethasone; Rd = lenalidomide, dexamethasone; PFS = progression-free survival; HR = hazard ratio; CI = confidence interval; IMWG = International Myeloma Working Group; EBMT = European blood and marrow transplantation
KRd-arma (N = 396)
KRd arma (N = 396)
KRd-armen (Kyprolis, lenalidomid og dexamethason) i studie PX-171-009 tyder på, at der kan være en potentiel dosissammenhæng for følgende bivirkninger: hjerteinsufficiens (Kd 8,2 %, KRd 6,4 %), dyspnø (Kd 30,9 %, KRd 22,7 %), hypertension (Kd 25,9 %, KRd 15,8 %) og pulmonal hypertension (Kd 1,3 %, KRd 0,8 %).
Kyprolis, lenalidomide and dexamethasone (KRd) arm of study PX-171-009 suggest that there may be a potential dose relationship for the following adverse reactions: cardiac failure (Kd 8.2%, KRd 6.4%), dyspnoea (Kd 30.9%, KRd 22.7%), hypertension (Kd 25.9%, KRd 15.8%), and pulmonary hypertension (Kd 1.3%, KRd 0.8%).
Kreatinfosfokinase (CPK)  2,5 x ULN
Creatine phosphokinase (CPK)  2.5 x ULN
Kreatiniclearance (ml/min) =
CLcr (ml/min) =
Kreatinin- clearance (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73 m2)
Kreatinin- clearance (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73m2)
kreatinin- clearance**
Creatinine clearance decreased
Kreatinin- niveau
Creatinine elevation
Kreatinin-clearance
Creatinine Clearance
kreatinin-clearance benyttes ved
creatinine clearance is used for dose
Kreatinin-clearance og/eller plasma- cystatin C
Creatinine clearance and/or plasma cystatin C
Kreatinin-clearance skal være  45 ml/min.
Creatinine clearance should be ≥ 45 ml/min.
Kreatinin-clearance ved baseline (ml/min)
Baseline Creatinine Clearance (ml/min)
Kreatininclearan ce (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73m2)
Kreatininclearan- ce (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73 m2)
Kreatininclearance
Serum Creatinine
Kreatininclearance (CLcr) (ml/min)
Creatinine Clearance (ml/min)
Kreatininclearance (ml/min)   serumkreatinin (mol / l)
serum creatinine (µmol/L)
Kreatininclearance (ml/min/1,73 m2)
Creatinine clearance
Kreatininclearance (ml/min/1,73 m2)
Creatinine clearance (ml/min/1.73m2 )
Kreatininclearance skal være  45 ml/min.
Creatinine clearance should be ≥ 45 ml/min.
Kreatininclearance  30 ml/min (monoterapi), serumkreatinin  1,5 mg/dl ( 132,6 μmol/l) eller kreatininclearance  60 ml/min (kombinationsterapi)
Creatinine clearance  30 ml/min (monotherapy), serum creatinine  1.5 mg/dl ( 132.6 μmol/l) or creatinine clearance  60 ml/min (combination therapy)
Kreatininclearancea (ml/min)
Creatinine clearancea
Kreatininclearancea (ml/min)
Creatinine clearancea (ml/min)
Kreatininphosphokinase
Creatinine phosphokinase
Kreatininstigninger på >50 % fra baseline.) og ikke summarisk frekvens af bivirkningsindberetning. e f.eks. konjunktival, retinal, intraokulær blødning
Creatinine increases of >50% from baseline.) and not crude adverse event report frequency. e e.g. conjunctival, retinal, intraocular bleeding
kreatinkinase
phosphokinase
Kreatinkinase og myopati
Creatine phosphokinase and myopathy
kreatinphospho- kinase
blood creatine phospho-kinase increased
Kreaturer (malkekøer og kvier)
Cattle (dairy cows and heifers).
Kreaturer (malkekøer og kvier).
Cattle (dairy cows and heifers).
Kreaturer geder
Bovine, caprine
Kreaturer, geder,
Bovine, caprine
Kreaturer, geder, Grise kanin,
Bovine, caprine, porcine, rabbit, Equidae
Kreaturer, geder, grise kanin, dyr tilhørende hestefamilien
Bovine, caprine, porcine, rabbit, Equidae
Kreaturer, geder, grise, kanin, dyr af hestefamili en
Bovine, caprine, porcine, rabbit, Equidae
Kreaturer, geder, grise, kanin, dyr af hestefamilien
Bovine, caprine, porcine, rabbit, Equidae
Kreaturer, geder, svin, kaniner,dyr tilhørende hestefamilien
Bovine, caprine, porcine, rabbit, Equidae
Kreaturer,geder
Bovine, caprine
Kreaturerne genkontrolleres i op til 4 dage efter dosering for at observere tegn på, om det intraruminale indlæg har lejret sig i spiserøret.
Recheck cattle for up to 4 days after dosing to observe for signs of an intraruminal device lodging in the oesophagus.
Kredsløbskollaps; hypotension
Circulatory collapse; Hypotension
Kredsløbsproblemer
Circulatory problems
kredsløbsproblemer (blandt symptomerne er: smerter i arme og ben, kulde i lemmenes ekstremiteter) øget tendens til blødning eller blå mærker
blood circulation problems (symptoms include: pain in the legs or arms, coldness of the extremities of the limbs) increased tendency to bleed or bruise
kredsløbsproblemer i milten
circulatory problems in the spleen
Kredsløbsproblemer som gør fingre og tæer følelsesløse og blege,
Circulation problems which make the toes and fingers numb and pale
Kredsløbsproblemer såsom for lavt eller for højt blodtryk
Circulation problems such as low or high blood pressure
Kredsløbsproblemer såsom for lavt eller for højt blodtryk
Circulation problems such as low or high blood pressure,
Kredsløbssvigt, petekkier, vasospasme.
Circulatory failure, petechia, vasospasm
kredsløbssygdomme med sovende eller kolde hænder eller fødder eller muskelkramper i benene
disorders of blood circulation resulting in pins and needles or cold hands or feet or muscle cramps in the legs
Krepitation i led
joint crepitation
Kriterie for doserings- genoptagelsea
Resumption criteriaa
Kriterier for cytogenetisk respons: Major cytogenetisk respons omfattede komplet (0 % Ph+ metafaser fra knoglemarven eller < 1 % positive celler fra fluorescens-in situ-hybridisering [FISH]) eller delvist (1-35 %) cytogenetisk respons.
Cytogenetic Response criteria: Major Cytogenetic response included Complete (0% Ph+ metaphases from bone marrow or < 1% positive cells from fluorescent in situ hybridization [FISH]) or partial (1%-35%) cytogenetic responses.
Kriterier for kvinder, som ikke er i den fertile alder
Criteria for women of non-childbearing potential
Kriterier for opblussen af sygdommen var defineret som en forværring på ≥ 30 % i forhold til baseline af ≥ 3 ud af 6 pædiatrisk ACR- hovedkriterier, ≥ 2 aktive led og en forbedring på > 30 % i ikke flere end 1 af de 6 kriterier.
Disease flare criteria were defined as a worsening of  30% from baseline in  3 of 6 Pediatric ACR core criteria,  2 active joints, and improvement of  30% in no more than 1 of the 6 criteria.
Kriterier for opblussen af sygdommen var defineret som en forværring på ≥ 30 % i forhold til baseline af ≥ 3 ud af 6 pædiatrisk ACR- hovedkriterier, ≥ 2 aktive led og en forbedring på > 30 % i ikke mere end 1 af de 6 kriterier.
Disease flare criteria were defined as a worsening of  30% from baseline in  3 of 6 Pediatric ACR core criteria,  2 active joints, and improvement of  30% in no more than 1 of the 6 criteria.
Kriterier for udvælgelse af patienter, herunder at pioglitazon ikke bør anvendes som førstevalgsbehandling og understregning af behovet for regelmæssig kontrol af behandlingens gavn.
Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit.
Kriteriet for genopfyldningens nøjagtighed over de 4 genopfyldninger var også lig den for Insuman Implantable administreret ved kontinuert intraperitoneal infusion i forhold til semi-syntetisk human insulin (per protokol population: gennemsnitlig forskel: - 3.15 ± 1,34; [95 % CI: -5,81; -0,50]).
Insuman Implantable administered in continuous intraperitoneal infusion was also similar to semi-synthetic human insulin as demonstrated by the refill accuracy criteria over the 4-refill cycles (per protocol population: mean difference: -3.15 ± 1.34; [95% CI: -5.81; -0.50]).
Kritisk organblødning*
Critical organ bleeding
Krka (UK) Ltd.
Krka UK Ltd.
KRKA Belgium, SA
KRKA Belgium, SA.
KRKA Farmacéutica, S.L.
KRKA Farmacéutica, S.L. Tel: +34 911 61 03 81
KRKA Romania S.R.L., Bucharest Tel: + 4021 310 66 05
KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05
KRKA, Belgien, SA
KRKA Belgium, SA.
KRKA, d.d., Novo mesto Tél/Tel: + 32 (0)3 321 63 52
Luxembourg/Luxemburg KRKA, d.d., Novo mesto Tél/Tel: + 32 (0)3 321 63 52
KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenien
KRKA, d.d., Novo mesto Šmarješka cesta 6 8501 Novo mesto Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
KRKA, d. d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenië
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA-POLSKA Sp. z. o.o. ul.
KRKA-POLSKA Sp.z. o.o. ul.
Kroatien
14.
Kroatien/Hrvatska
Croatia/ Hrvatska
Kromatopsi
Chromatopsia
Kromaturi
chromaturia.
Kromaturi
disorders
Kromaturi (se ovenfor).
Chromaturia (see above).
Kromaturin (blå-grøn farvning af urinen) er blevet rapporteret i forbindelse med zaleplon overdosering.
Chromaturia (blue- green urine discolouration) has been reported with zaleplon overdose.
Kromogen analyse
Chromogenic assay
Kromogen analyse Gennemsnit (område)
Chromogenic assay Median (range)
Kromogen analyse Middelværdi ± SD
Chromogenic assay Mean ± SD
Kromogen analyse Middelværdi ± SD
PK parameter
Kromogene analyseresultater Median; (Q1, Q3) (IE/dL / IE/kg)
Chromogenic assay results Median; (Q1; Q3) (IU/dL / IU/kg)
Kromosomale afvigelser blev kategoriseret efter Döhner’s hierarkiske model.
Chromosomal aberrations were categorized according to Döhner’s hierarchical model.
kronisk (langvarig) hepatitis B (en leversygdom, der skyldes betændelse med hepatitis B-virus).
chronic (long-term) hepatitis B (a disease of the liver due to infection with the hepatitis B virus).
Kronisk (n= 387)
Chronic (n= 387)
Kronisk administration af omalizumab i dosisniveauer på op til 250 mg/kg (mindst 14 gange den højst anbefalede kliniske dosis i mg/kg ifølge den anbefalede doseringstabel) var veltolereret hos ikke- humane primater (både voksne og unge dyr), med undtagelse af et dosisrelateret og aldersafhængigt fald i trombocytter, med en større sensibilitet hos unge dyr.
Chronic administration of omalizumab at dose levels of up to 250 mg/kg (at least 14 times the highest recommended clinical dose in mg/kg according to the recommended dosing table) was well tolerated in non-human primates (both adult and juvenile animals), with the exception of a dose-related and age-dependent decrease in blood platelets, with a greater sensitivity in juvenile animals.
kronisk allograftnefropati (CAN), ventralhernie
chronic allograft nephropathy (CAN), incisional hernia
Kronisk allograftnefropati/Interstitiel fibrose og tubulær atrofi (IFTA)
Chronic Allograft Nephropathy/Interstitial Fibrosis and Tubular Atrophy (IFTA)
Kronisk artrit
Chronic arthritis
Kronisk betændelsestilstand i lungerne
Chronic inflammatory condition of the lungs
Kronisk co-administration af potente CYP3A4- inducere (f.eks. phenytoin, carbamazepin, rifampicin, phenobarbital eller naturlægemidler indeholdende perikon [Hypericum perforatum]) med cabozantinib bør derfor undgås.
Chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampicin, phenobarbital or herbal preparations containing St. John’s Wort [Hypericum perforatum]) with cabozantinib should therefore be avoided.
Kronisk eller akut overdosering er usandsynlig på baggrund af den totale injice- rede mængde.
Chronic or acute overdose is unlikely to occur given the total injection amount.
Kronisk eller akut pancreatitis med undtagelse af akut pancreatitis, der skyldes alvorlig hypertriglyceridæmi
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridaemia
Kronisk eller alvorlig obstipation eller sequelae efter obstipation i anamnesen eller kendt eller mistanke om mekanisk gastrointestinal obstruktion.
A history of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction.
Kronisk fase (n= 165)b
Chronic phase
Kronisk fase, nydiagnosticeret: Denne fase III undersøgelse hos voksne patienter sammenlignede enkeltstof-behandling med imatinib med behandling med en kombination af interferon-alfa (IFN) og cytarabin (Ara-C).
Chronic phase, newly diagnosed: This phase III study in adult patients compared treatment with either single-agent imatinib or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C).
Kronisk graft-versus-host sygdom (en komplikation, som kan optræde efter en stamcelle- eller knoglemarvstransplantation, hvor de nyligt transplanterede donorceller angriber patientens krop)
Chronic graft-versus-host disease (a complication that can occur after a stem-cell or bone marrow transplantation in which the newly transplanted donor cells attack the patient’s body)
Kronisk hepatitis B – voksne patienter
Chronic hepatitis B – adult patients
Kronisk hepatitis B: Behandlingens optimale varighed er ukendt.
Chronic hepatitis B: The optimal duration of treatment is unknown.
Kronisk hepatitis B: Steady-state tenofovir-eksponering hos HBV-inficerede unge patienter (i alderen 12 til < 18 år), som fik daglige orale doser på 245 mg tenofovirdisoproxil (som fumarat), svarede til de eksponeringer, der blev opnået hos voksne, som fik 245 mg tenofovirdisoproxil (som fumarat) en gang dagligt.
Chronic hepatitis B: Steady-state tenofovir exposure in HBV infected adolescent patients (12 to < 18 years of age) receiving an oral daily dose of tenofovir disoproxil 245 mg (as fumarate) was similar to exposures achieved in adults receiving once-daily doses of tenofovir disoproxil 245 mg (as fumarate).
Kronisk hepatitis C - behandlingsnaive voksne patienter
Chronic hepatitis C – treatment-naïve adult patients
Kronisk hepatitis C - Kombinationsbehandling med ribavirin
Chronic Hepatitis C - Combination therapy with ribavirin
Kronisk hepatitis C hos børn og unge
Chronic hepatitis C in children and adolescent population
Kronisk hepatitis C Responsets forudsigelighed
Chronic hepatitis C
Kronisk hepatitis C – behandlingserfarne voksne patienter
Chronic hepatitis C – treatment-experienced adult patients
Kronisk hepatitis hos patienter, som bliver eller for nylig er blevet behandlet med immunsuppressive stoffer, bortset fra nedtrapning af korttids-kortikosteroid.
Chronic hepatitis in patients who are being or have been treated recently with immunosuppressive agents excluding short term corticosteroid withdrawal.
Kronisk hjertesvigt hos voksne patienter med en puls på mindst 75 slag i minuttet.
Chronic heart failure in adult patients whose heart rate is over or equal to 75 beats per minute.
Kronisk immun (idiopatisk) trombocytopeni
Chronic immune (idiopathic) thrombocytopenia
kronisk immun (idiopatisk) trombocytopenisk purpura (ITP), en sygdom, hvor patientens immunsystem ødelægger blodpladerne (bestanddele i blodet, som er vigtige for blodets evne til at størkne).
long-term immune (idiopathic) thrombocytopenic purpura (ITP), a disease in which the patient’s immune system destroys the platelets (components in the blood that help it to clot).
Kronisk inflammatorisk demyeliniserende polyneuropati (CIDP)*
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Kronisk inflammatorisk demyeliniserende polyneuropati (CIDP).
Chronic inflammatory demyelinating polyneuropathy (CIDP).
Kronisk kolestase er en medfødt eller arvelig sygdom, hvor galde ikke kan udskilles fra leveren til tarmen.
Congenital or hereditary chronic cholestasis is an inherited disease causing problems with the flow of bile from the liver to the gut.
Kronisk leddegigt (reumatoid artrit), psoriasisgigt (psoriasis artrit) og rygsøjlegigt (aksial spondylartrit), herunder en form for rygsøjlegigt, som kaldes ankyloserende spondylit Den sædvanlige dosis er 50 mg en gang om ugen givet som en injektion under huden.
Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis The usual dose is 50 mg once a week as an injection under the skin.
Kronisk leddegigt (reumatoid artrit), psoriasisgigt (psoriasis artrit) og rygsøjlegigt (aksial spondylartrit), herunder en form for rygsøjlegigt, som kaldes ankyloserende spondylit Den sædvanlige dosis er 50 mg en gang om ugen, givet som en injektion under huden.
Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis The usual dose is 50 mg once a week as an injection under the skin.
Kronisk lymfatisk leukæmi (CLL) i kombination med chlorambucil1
Chronic lymphocytic leukaemia (CLL, in combination with chlorambucil1)
Kronisk lymfatisk leukæmi (CLL), en kræftform, der påvirker den type hvide blodlegemer, der kaldes lymfocytter, og som også involverer lymfeknuderne.
Chronic Lymphocytic Leukaemia (CLL) a type of cancer affecting white blood cells called lymphocytes that also involves the lymph nodes.
Kronisk lymfatisk leukæmi (CLL)/Waldenströms makroglobulinæmi (WM)
Chronic Lymphocytic Leukaemia (CLL)/Waldenström’s macroglobulinaemia (WM)
Kronisk lymfatisk leukæmi (også kaldet ”CLL”)
Chronic lymphocytic leukaemia (also called “CLL”)
Kronisk lymfatisk leukæmi er blodkræft udgående fra en type hvide blodlegemer, der kaldes B-lymfocytter.
CLL is a cancer of B-lymphocytes, a type of white blood cells.
Kronisk lymfatisk leukæmi er den mest almindelige form for leukæmi hos voksne.
Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia.
Kronisk lymfatisk leukæmi og follikulært lymfom er begge kræfttyper i blodet, der påvirker den type hvide blodlegemer, der hedder B lymfocytter.
CLL and FL are types of cancer that affect white blood cells called “B-lymphocytes”.
Kronisk lymfatisk leukæmi og Waldenströms makroglobulinæmi
Chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia
Kronisk malabsorptionssyndrom
Chronic malabsorption syndrome
Kronisk malabsorptionssyndrom.
Chronic malabsorption syndrome.
Kronisk myeloid leukæmi (CML) i blastkrise.
Chronic myeloid leukaemia (CML) in blast crisis.
Kronisk myeloid leukæmi (CML), en form for kræft, som angriber de hvide blodlegemer, hvori der er granulocytter (en form for hvide blodlegemer), som begynder at vokse ukontrolleret.
chronic myeloid leukaemia (CML), a cancer of the white blood cells in which granulocytes (a type of white blood cell) start growing out of control.
Kronisk myeloid leukæmi: 4-5 millioner IE/m2 daglig injiceret subkutant (under huden).
Chronic Myelogenous Leukaemia: 4-5 million IU/m2 daily injected subcutaneously (under the skin).
Kronisk myelomonocytær leukæmi(2)(4), pankreatisk adenokarcinom5
Chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5)
Kronisk nyresvigt.
Chronic renal failure
Kronisk nyresvigt.
Chronic renal failure.
Kronisk obstruktiv lungesygdom (KOL), for at nedsætte hyppigheden af anfald med forværring af dine symptomer.
Chronic obstructive pulmonary disease (COPD), to reduce the number of flare ups of symptoms.
kronisk obstruktiv lungesygdom,
chronic obstructive pulmonary disease,
kronisk obstruktiv lungesygdom,
chronic obstructive pulmonary disease, pneumonitis,
Kronisk obstruktiv lungesygdom, lungegranulom, vasomotorisk rinit
Chronic obstructive pulmonary disease, pulmonary granuloma, vasomotor rhinitis
Kronisk overdosering og neurologiske forstyrrelser
Chronic overdose and neurological disorders
kronisk smerte
chronic pain
Kronisk spontan nældefeber
Chronic spontaneous urticaria (CSU)
Kronisk spontan nældefeber (CSU)
Chronic spontaneous urticaria (CSU)
Kronisk spontan urticaria
Chronic spontaneous urticaria (CSU)
Kronisk svær leversygdom
Chronic severe hepatic disease
Kronisk sygdom i leddene (spondylartropati); sygdom, hvor immunsystemet angriber de kirtler, der producerer kropsvæsker som tårer og spyt (Sjögrens syndrom), smertefulde led; muskelsmerter, ømme eller svage muskler, som ikke skyldes fysisk aktivitet (myopati)
Chronic disease of joints (spondyloarthropathy); disease in which the immune system attacks the glands that make moisture for the body, such as tears and saliva (Sjogren’s syndrome), painful joints; myopathy (aching muscles, muscle tenderness of weakness, not caused by exercise)
Kronisk toksicitet: I et 26-ugers gentagen dosis toksicitetsstudie i rhesusaber med intramuskulær administration én gang ugentlig, og givet i kombination med en anden immunmodulerende substans, et anti-CD40 ligand monoklonalt antistof, blev der ikke påvist noget immunrespons over for interferon-beta-1a, og der var ingen tegn på toksicitet.
Chronic Toxicity: In a 26-week repeated-dose toxicity study in rhesus monkeys by intramuscular route once per week, administered in combination with another immunomodulating agent, an anti CD40 ligand monoclonal antibody, no immune response toward interferon beta-1a and no signs of toxicity were demonstrated.
kronisk tromboembolisk pulmonal hypertension (CTEPH).
chronic thromboembolic pulmonary hypertension (CTEPH).
kronisk tør mund, der har medført parodontal sygdom eller svampeinfektion i munden
Chronic dry mouth that has resulted in periodontal disease or oral fungal infections
kronisk tør mund, der har medført parodontal sygdom eller svampeinfektion i munden
Chronic dry mouth that has resulted in periodontal disease or oral fungal infections;
Kronisk venstresidig hjerteinsufficiens (NYHA II-IV).
Congestive heart failure (NYHA II-IV).